All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-03-10T15:20:26.000Z

BOB1 intracellular transcription factor is a target for TCR-based therapy in MM

Mar 10, 2017
Share:

Bookmark this article

In January 2017 Jahn L. and colleagues from Leiden University Medical Center, The Netherlands published a paper in Blood, describing a pre-clinical study in which TCR gene transfer of BOB1 (intracellular B-cell specific transcription factor) conferred reactivity to recipient T cells and potent in-vivo anti-tumor activity in a mouse model of Multiple Myeloma (MM).

Key Findings

Identification of BOB1 epitopes and isolation of BOB1 reactive T cell clones

  • POU2AF1 (which encodes BOB1) was isolated as a B-cell specific gene
  • Four MHC-presented peptides of BOB1 were identified using the B-LCL ligandome, 3 of which bound to HLA-B*07:02
  • Stable pMHC tetramers for each BOB1-derived peptide were used to isolate/enrich T-cell clones from HLA-A2-/B7- individuals
  • Two T-cell clones: 3C10 recognizing BOB1245: A2 and 4G11 recognizing BOB144:B7, demonstrated specific recognition of peptide-pulsed target cells and reactivity against endogenously processed and presented peptide
  • T-cell clone 4G11 efficiently recognized all HLA-B7+ primary (BOB1-expressing) B-cell malignancies tested, including 5 CLLs, 4 ALLs, 3 MCLs, and 4 MMs, as well as K562 cells transduced with BOB1 (3C10 had insufficient avidity at this stage)
  • The 4G11 T-cell clone lacked reactivity towards healthy hematopoietic non-B cells and non-hematopoietic cells, indicating no off-target effects

TCR gene transfer confers reactivity to recipient T cells

  • A codon-optimized 4G11 TCR clone was developed along with NGF-R as a marker gene for selection/enrichment of transduced T cells
  • Expression of 4G11, on retrovirally transduced CD8+ T cells from an HLA-B7+ healthy individual, was confirmed by tetramer binding.
  • These clones:
    • readily recognized BOB1-expressing HLA-B7+ stimulator cells (MM cell lines – U9, U266, LCL-JY) as well as two ALL (acute lymphoblastic leukemia) cell lines
    • efficiently lysed several primary HLA-B7+ malignant cell samples
    • readily lysed HLA-B7+ primary MM samples at low effector-to-target ratios
    • did not lyse autologous activated T cells or CD14+ monocytes
    • proliferated upon stimulation with various BOB1-expressing HA-B7+ primary samples (including several MM cell lines)
  • No lysis was observed for mock transduced cells, indicating specificity of the TCR-4G11 clone

In-vivo mouse model for MM

  • U266 cells (HLA-B7+) were expanded in an NSG mouse for 3 weeks before introduction of TCR-4G11 T cells
  • Significant reduction of tumor cells in the bone marrow (BM) was observed with TCR-4G11 T cells but not with mock transduced cells

In conclusion, a chimeric BOB1-specific TCR clone conferred high anti-tumor reactivity to transduced T cells when tested in an in-vivo mouse xenograft model for established MM, and therefore paves the way for engineered T cells as a future treatment option for MM.

Abstract

Immunotherapy for hematological malignancies or solid tumors by administration of monoclonal antibodies or T cells engineered to express chimeric antigen receptors or T-cell receptors (TCRs) has demonstrated clinical efficacy. However, antigen-loss tumor escape variants and the absence of currently targeted antigens on several malignancies hamper the widespread application of immunotherapy. We have isolated a TCR targeting a peptide of the intracellular B cell-specific transcription factor BOB1 presented in the context of HLA-B*07:02. TCR gene transfer installed BOB1 specificity and reactivity onto recipient T cells. TCR-transduced T cells efficiently lysed primary B-cell leukemia, mantle cell lymphoma, and multiple myeloma in vitro. We also observed recognition and lysis of healthy BOB1-expressing B cells. In addition, strong BOB1-specific proliferation could be demonstrated for TCR-modified T cells upon antigen encounter. Furthermore, clear in vivo antitumor reactivity was observed of BOB1-specific TCR-engineered T cells in a xenograft mouse model of established multiple myeloma. Absence of reactivity toward a broad panel of BOB1- but HLA-B*07:02+ nonhematopoietic and hematopoietic cells indicated no off-target toxicity. Therefore, administration of BOB1-specific TCR-engineered T cells may provide novel cellular treatment options to patients with B-cell malignancies, including multiple myeloma.

  1. Jahn L.et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood. 2017 Mar 9;129(10):1284-1295. DOI: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox